218 related articles for article (PubMed ID: 28358507)
1. Protein Degradation via CRL4
Hansen JD; Condroski K; Correa M; Muller G; Man HW; Ruchelman A; Zhang W; Vocanson F; Crea T; Liu W; Lu G; Baculi F; LeBrun L; Mahmoudi A; Carmel G; Hickman M; Lu CC
J Med Chem; 2018 Jan; 61(2):492-503. PubMed ID: 28358507
[TBL] [Abstract][Full Text] [Related]
2. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase.
Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP
Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
[TBL] [Abstract][Full Text] [Related]
4. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP
J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720
[TBL] [Abstract][Full Text] [Related]
5. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.
Hagner PR; Man HW; Fontanillo C; Wang M; Couto S; Breider M; Bjorklund C; Havens CG; Lu G; Rychak E; Raymon H; Narla RK; Barnes L; Khambatta G; Chiu H; Kosek J; Kang J; Amantangelo MD; Waldman M; Lopez-Girona A; Cai T; Pourdehnad M; Trotter M; Daniel TO; Schafer PH; Klippel A; Thakurta A; Chopra R; Gandhi AK
Blood; 2015 Aug; 126(6):779-89. PubMed ID: 26002965
[TBL] [Abstract][Full Text] [Related]
6. Selective Degradation of GSPT1 by Cereblon Modulators Identified via a Focused Combinatorial Library.
Powell CE; Du G; Che J; He Z; Donovan KA; Yue H; Wang ES; Nowak RP; Zhang T; Fischer ES; Gray NS
ACS Chem Biol; 2020 Oct; 15(10):2722-2730. PubMed ID: 32865967
[TBL] [Abstract][Full Text] [Related]
7. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
Surka C; Jin L; Mbong N; Lu CC; Jang IS; Rychak E; Mendy D; Clayton T; Tindall E; Hsu C; Fontanillo C; Tran E; Contreras A; Ng SWK; Matyskiela M; Wang K; Chamberlain P; Cathers B; Carmichael J; Hansen J; Wang JCY; Minden MD; Fan J; Pierce DW; Pourdehnad M; Rolfe M; Lopez-Girona A; Dick JE; Lu G
Blood; 2021 Feb; 137(5):661-677. PubMed ID: 33197925
[TBL] [Abstract][Full Text] [Related]
8. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH
Science; 2018 Nov; 362(6414):. PubMed ID: 30385546
[TBL] [Abstract][Full Text] [Related]
9. CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.
Hansen JD; Correa M; Alexander M; Nagy M; Huang D; Sapienza J; Lu G; LeBrun LA; Cathers BE; Zhang W; Tang Y; Ammirante M; Narla RK; Piccotti JR; Pourdehnad M; Lopez-Girona A
J Med Chem; 2021 Feb; 64(4):1835-1843. PubMed ID: 33591756
[TBL] [Abstract][Full Text] [Related]
10. Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators.
Nishiguchi G; Keramatnia F; Min J; Chang Y; Jonchere B; Das S; Actis M; Price J; Chepyala D; Young B; McGowan K; Slavish PJ; Mayasundari A; Jarusiewicz JA; Yang L; Li Y; Fu X; Garrett SH; Papizan JB; Kodali K; Peng J; Pruett Miller SM; Roussel MF; Mullighan C; Fischer M; Rankovic Z
J Med Chem; 2021 Jun; 64(11):7296-7311. PubMed ID: 34042448
[TBL] [Abstract][Full Text] [Related]
11. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
[TBL] [Abstract][Full Text] [Related]
12. Trends in Neosubstrate Degradation by Cereblon-Based Molecular Glues and the Development of Novel Multiparameter Optimization Scores.
Szewczyk SM; Verma I; Edwards JT; Weiss DR; Chekler ELP
J Med Chem; 2024 Jan; 67(2):1327-1335. PubMed ID: 38170610
[TBL] [Abstract][Full Text] [Related]
13. UBE2G1 governs the destruction of cereblon neomorphic substrates.
Lu G; Weng S; Matyskiela M; Zheng X; Fang W; Wood S; Surka C; Mizukoshi R; Lu CC; Mendy D; Jang IS; Wang K; Marella M; Couto S; Cathers B; Carmichael J; Chamberlain P; Rolfe M
Elife; 2018 Sep; 7():. PubMed ID: 30234487
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
Petzold G; Fischer ES; Thomä NH
Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
[TBL] [Abstract][Full Text] [Related]
15. p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.
Nguyen TV; Li J; Lu CJ; Mamrosh JL; Lu G; Cathers BE; Deshaies RJ
Proc Natl Acad Sci U S A; 2017 Apr; 114(14):3565-3571. PubMed ID: 28320958
[TBL] [Abstract][Full Text] [Related]
16. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.
Schafer PH; Ye Y; Wu L; Kosek J; Ringheim G; Yang Z; Liu L; Thomas M; Palmisano M; Chopra R
Ann Rheum Dis; 2018 Oct; 77(10):1516-1523. PubMed ID: 29945920
[TBL] [Abstract][Full Text] [Related]
17. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG
Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623
[TBL] [Abstract][Full Text] [Related]
18. Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders.
Ishoey M; Chorn S; Singh N; Jaeger MG; Brand M; Paulk J; Bauer S; Erb MA; Parapatics K; Müller AC; Bennett KL; Ecker GF; Bradner JE; Winter GE
ACS Chem Biol; 2018 Mar; 13(3):553-560. PubMed ID: 29356495
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.
Meng F; Xu C; Park KS; Kaniskan HÜ; Wang GG; Jin J
J Med Chem; 2022 Aug; 65(15):10611-10625. PubMed ID: 35895319
[TBL] [Abstract][Full Text] [Related]
20. Targeting cereblon in hematologic malignancies.
Fuchs O
Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
